Blarcamesine is a very interesting molecule. It’s a focus on autophagy with a specific target of a sigma-1 receptor. And the trials, that is the Phase IIb/III trials, show not only an efficacy in terms of ADAS-COG and CDR-SB scale, but also an impact on different biomarkers, including brain atrophy. So there is a reduction of the brain atrophy on the ITT population. But what is very interesting in this compound, it’s an oral compound...
Blarcamesine is a very interesting molecule. It’s a focus on autophagy with a specific target of a sigma-1 receptor. And the trials, that is the Phase IIb/III trials, show not only an efficacy in terms of ADAS-COG and CDR-SB scale, but also an impact on different biomarkers, including brain atrophy. So there is a reduction of the brain atrophy on the ITT population. But what is very interesting in this compound, it’s an oral compound. So there is no ARIA, there is no need for MRI monitoring. The side effects are transient and very manageable in routine. And the ability to move in the precision medicine field. Because Anavex have analyzed a part of the higher responders to treatment inside the whole ITT population. There are specific participants that carry wild-type sigma-1 and another that is related to collagen. And based on this specific profile, they have a higher response to treatment and a low risk of different side effects. So that means that for some of them, they could reach like 72% reduction of atrophy, for example, 85% impact on the cognitive decline and functional decline. So it’s not only another type of target that it’s like up to amyloid and tau because it’s related to atrophy that we both know as interfering before any mechanism of downstream effect of amyloid and tau. So it’s before this type of protein aspect. And in addition to that, it’s also very relevant to be able to identify the higher responders to treatment based on a GWAS approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
